Psychedelics

The pipeline of hallucinogenic and nonhallucinogenic psychedelic medicines is exploding.

When considering the 3-stage framework, perhaps a greater emphasis on pre-treatment phase research could help identify some of the more individual traits used to better predict patient outcomes.

As access becomes easier, pharmacists are more likely to encounter questions.

The DEA will have a hearing in December 2024 regarding the potential reclassification of cannabis to Schedule III, which could significantly impact the regulatory environment for pharmacies and their involvement in the cannabis market.

Previously, an independent advisory panel for the FDA rejected the use of MDMA-assisted therapy for posttraumatic stress disorder (PTSD), citing concerns of the reliability of the clinical trial data.

The authors note that the oral, at-home treatment can be a better alternative for patients by reducing inconveniences that come with the injectable and nasal administration methods.

Although the committee's vote is non-binding, it does raise questions about optimal evaluation of psychedelics in clinical trials.

The panelists expressed concerns about clinical trial data and concluded that the benefits do not outweigh the risks, but the FDA does not have to follow their recommendation.

This is the first FDA advisory committee meeting that will review a potential new posttraumatic stress disorder treatment in 25 years.

However, psychedelic medicine has a variety of barriers, including historical perception, access challenges, legal obstacles, and ethical questions.

Despite being a Schedule I drug, cannabis is increasingly used in oncology for symptom management, although data remains limited.

MDMA-assisted therapy and psilocybin currently lead the way with potential approvals by the FDA.

Psychedelic medicines such as psilocybin, MDMA, ketamine, and LSD have been shown to have a significant impact on conditions such as major depressive disorder, generalized anxiety disorder, and post-traumatic stress disorder in clinical trials.

LSD d-tartrate (MM-120) showed rapid improvements in patients with generalized anxiety disorder by day 2 of the study.

At 4 months, 75% of participants achieved remission and no longer showed signs of depression symptoms in a phase 2 clinical trial.

If clinical trials continue to show that psychedelics offer safe and long-lasting results, then psychedelic-assisted therapy could flourish as a treatment in the mental health space.

If approved, this would mark the first MDMA-assisted therapy and psychedelic-assisted therapy approved, calling for a reschedule of MDMA from Schedule I. A PDUFA was set for this summer.

The investigators note that psilocybin’s effectiveness in treating depressive symptoms and the positive reception among patients with cancer are encouraging continued research.

By combining the administration of psychedelic compounds with therapeutic support, ketamine-assisted therapy is proving remarkable efficacy in treating mental health conditions.

Ketamine topical cream may alleviate symptoms of PTSD without causing the adverse effects and abuse potential often associated with other forms of ketamine administration.

California is possibly on the verge of signing a bill that would decriminalize the personal possession of natural psychedelics for those aged 21 years and older.

KET01 could successfully treat treatment-resistant depression while limiting adverse effects in the home environment, according to the study.

The daily oral formulation of ketamine, KET01, has the potential to greatly improve the standard treatment practices for treatment-resistant depression, according to investigators.

Generic ketamine could cost as little as $5, which is significantly lower than the $800 per dose for the currently available S-ketamine nasal spray.

Quality standards and national regulation help to establish its role as medicine.

Further research and regulatory changes are needed, but psychedelic medicines may be able to treat or even cure mental illness in the future.

The use of psilocybin and psychedelic therapy can be a helpful tool for individuals with AUD and could have a positive outcome that can result in self compassion.

Renewed focus on the potential this drug can provide patients is upon us as we continue to strive for greater and better care and treatment for patients throughout US health systems.

Providing this treatment for patients with cancer may be a smoother transition for oncology professionals than they might expect.

The study will assess the use of the drug to treat impaired social motivation, or asociality, which is a difficult-to-treat symptom of schizophrenia that can cause significant functional impairment.